Cybin Inc.
corporate_fare Company Profile
Cybin Inc. (NASDAQ:HELP) is a publicly traded company in the Life Sciences sector. Wiseek monitors HELP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Helus Pharma wraps up enrollment early in pivotal Phase 3 APPROACH study; topline data still on deck for Q4 2026
- Cybin Reports Massive $148M Net Loss and High Cash Burn for FY26 Amidst Clinical Progress
- Annual Report Reveals Significant Increase in Net Loss and Cash Burn for FY2026
- Helus Pharma Closes $50M Offering, Fuels Phase 3 Trial and Pipeline Development
- Cybin Inc. Prices $50M Underwritten Offering to Fund Clinical Trials
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for HELP, detected from its recent SEC filings · based on capital-structure filings through 2026-06-25.
Underwritten Offering Priced · Substantial Share Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
HELP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.